146 related articles for article (PubMed ID: 21793333)
1. Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma.
Chen JH; Chen KY; Ma HI; Yu CP; Nieh S; Lee HS; Jin JS
Chin J Physiol; 2010 Aug; 53(4):234-44. PubMed ID: 21793333
[TBL] [Abstract][Full Text] [Related]
2. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma.
Hsu KF; Lin CK; Yu CP; Tzao C; Lee SC; Lee YY; Tsai WC; Jin JS
Dis Esophagus; 2009; 22(5):402-8. PubMed ID: 19207554
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas.
Li X; Zheng H; Hara T; Takahashi H; Masuda S; Wang Z; Yang X; Guan Y; Takano Y
Int J Oncol; 2008 Jul; 33(1):69-79. PubMed ID: 18575752
[TBL] [Abstract][Full Text] [Related]
4. Fascin, cortactin and survivin expression of melanocytic neoplasms and association with clinicopathological parameters and anatomic locations in Chinese people.
Gao HW; Yu CP; Lee HS; Nieh S; Chiang CP; Wang WM; Jin JS
Eur J Dermatol; 2010; 20(3):293-301. PubMed ID: 20400386
[TBL] [Abstract][Full Text] [Related]
5. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
6. Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters.
Lin CK; Su HY; Tsai WC; Sheu LF; Jin JS
Dis Markers; 2008; 25(1):17-26. PubMed ID: 18776588
[TBL] [Abstract][Full Text] [Related]
7. Gliosarcoma. A study of 13 tumors, including p53 and CD34 immunohistochemistry.
Sreenan JJ; Prayson RA
Arch Pathol Lab Med; 1997 Feb; 121(2):129-33. PubMed ID: 9126039
[TBL] [Abstract][Full Text] [Related]
8. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters.
Tsai WC; Jin JS; Chang WK; Chan DC; Yeh MK; Cherng SC; Lin LF; Sheu LF; Chao YC
J Histochem Cytochem; 2007 Sep; 55(9):955-62. PubMed ID: 17510372
[TBL] [Abstract][Full Text] [Related]
9. The correlation of cortactin and fascin-1 expression with clinicopathological parameters in pancreatic and ampulla of Vater adenocarcinoma.
Tsai WC; Lin CK; Lee HS; Gao HW; Nieh S; Chan DC; Jin JS
APMIS; 2013 Mar; 121(3):171-81. PubMed ID: 23030700
[TBL] [Abstract][Full Text] [Related]
10. Gliosarcoma with liposarcomatous differentiation: the new member of the lipid-containing brain tumors family.
Vlodavsky E; Konstantinesku M; Soustiel JF
Arch Pathol Lab Med; 2006 Mar; 130(3):381-4. PubMed ID: 16519569
[TBL] [Abstract][Full Text] [Related]
11. Fascin and cortactin expression is correlated with a poor prognosis in hepatocellular carcinoma.
Huang X; Ji J; Xue H; Zhang F; Han X; Cai Y; Zhang J; Ji G
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):633-9. PubMed ID: 22495401
[TBL] [Abstract][Full Text] [Related]
12. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
Rodriguez FJ; Scheithauer BW; Jenkins R; Burger PC; Rudzinskiy P; Vlodavsky E; Schooley A; Landolfi J
Am J Surg Pathol; 2007 Mar; 31(3):351-62. PubMed ID: 17325476
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features of primary and postirradiation cerebral gliosarcoma.
Perry JR; Ang LC; Bilbao JM; Muller PJ
Cancer; 1995 Jun; 75(12):2910-8. PubMed ID: 7773942
[TBL] [Abstract][Full Text] [Related]
14. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters.
Lee YY; Yu CP; Lin CK; Nieh S; Hsu KF; Chiang H; Jin JS
Dis Markers; 2009; 26(1):9-18. PubMed ID: 19242064
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry of gliosarcoma with liposarcomatous differentiation.
Fukuda T; Yasumichi K; Suzuki T
Pathol Int; 2008 Jun; 58(6):396-401. PubMed ID: 18477220
[TBL] [Abstract][Full Text] [Related]
16. An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile.
Sato Y; Deguchi S; Norose T; Oishi T; Mitsuya K; Sugino T; Akiyama Y; Nagashima T; Urakami K; Shimoda Y; Ohshima K; Hayashi N; Yamaguchi K
Nagoya J Med Sci; 2023 Nov; 85(4):828-835. PubMed ID: 38155632
[TBL] [Abstract][Full Text] [Related]
17. Primary gliosarcoma of the brain: radiologic and histopathologic features.
Romero-Rojas AE; Diaz-Perez JA; Ariza-Serrano LM; Amaro D; Lozano-Castillo A
Neuroradiol J; 2013 Dec; 26(6):639-48. PubMed ID: 24355182
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
[TBL] [Abstract][Full Text] [Related]
19. Intraventricular gliosarcoma with dual sarcomatous differentiation: A unique case.
Poyuran R; Bn N; Reddy YVK; Savardekar AR
Neuropathology; 2017 Aug; 37(4):346-350. PubMed ID: 28261869
[TBL] [Abstract][Full Text] [Related]
20. Preferential recurrence of a sarcomatous component of a gliosarcoma after boron neutron capture therapy: case report.
Miyatake S; Kuwabara H; Kajimoto Y; Kawabata S; Yokoyama K; Doi A; Tsuji M; Mori H; Ono K; Kuroiwa T
J Neurooncol; 2006 Jan; 76(2):143-7. PubMed ID: 16234987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
